Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue
Product revenue	$ 1,500,722	$ 2,065,030
Cost of product sales	618,099	1,161,641
Gross profit	882,623	903,389
Operating expenses
Research and development	322,165	167,287
Sales and marketing	500,255	241,400
General and administrative	1,220,705	863,743
Total operating expenses	2,043,125	1,272,430
Operating loss	(1,160,502)	(369,041)
Other income (expenses)
Interest income	8,237	0
Interest expense	0	(177,308)
Amortization of deferred financing costs	0	(13,022)
Total other income (expenses)	8,237	(190,330)
Net Loss	(1,152,265)	(559,371)
Net loss attributable to non-controlling interest	120,783	0
Net Loss attributable to BioLife Solutions, Inc.	$ (1,031,482)	$ (559,371)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc.	$ (0.09)	$ (0.10)
Basic and diluted weighted average common shares used to calculate net loss per common share	12,100,588	5,568,802